China Biologic Named to Forbes Magazine's Fifth Annual List of Asia's '200 Best Under a Billion'

TAI'AN CITY, China, Oct. 21 /PRNewswire-Asia/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in China, today announced that the Company was named on Forbes Magazine's fifth annual list of Asia's "200 Best Under a Billion" for the year 2009.

To assemble its Best Under a Billion for the Asia-Pacific region, Forbes considered only listed entities with under $1 billion in sales that have posted solid top and bottom-line gains and appear to be headed for more. The 200 Asia-Pacific companies were selected based on their: profitability, growth, modest indebtedness and future prospects this year (for a more precise methodology, go online to http://www.forbes.com/BUB ). According to Forbes, this year's selection were survivors of unprecedented dislocations in the global economy over the past 12 months, disrupted supply chains, frozen lines of credit, depleted consumer coffers and business spending hibernation, who seized opportunities rising from the economic uncertainty. China Biologic was one of only 78 companies in China and Hong Kong to make the prestigious list.

"We are pleased that Forbes Magazine has recognized China Biologic as one of the Asia-Pacific region's best small and mid-sized companies," said Mr. Chao Ming Zhao, the Company's Chief Executive Officer. "We believe that this accolade reflects our strong financial performance as well as our position as the leading non-state owned, plasma-based biopharmaceutical company in China."

About China Biologic Products, Inc.

China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. For more information please visit the Company's website http://www.chinabiologic.com

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the significance of the Company's recognition on Forbes Magazine's list of "Asia's 200 Best Under a Billion" for the year 2009; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Y. Tristan Kuo

Chief Financial Officer

China Biologic Products, Inc.

Tel: +86-538-6202206

Email: IR@chinabiologic.com

Web: http://www.chinabiologic.com

Investor Relations Contact:

Mr. Crocker Coulson, President

CCG Investor Relations

Tel: +1-646-213-1915 (NY office)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgir.com